약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 5.

Table. 5.

The number of serious adverse events of baricitinib

Serious adverse events
number (%)
Respiratory system disorders 6 (5.3)
Pneumonia 4 (3.5)
Pulmonary infiltration 1 (0.9)
Dyspnoea 1 (0.9)
Body as a whole-general disorders 3 (2.7)
Asthenia 2 (1.8)
Condition aggravated 1 (0.9)
Urinary system disorders 3 (2.7)
Pyelonephritis 3 (2.7)
Vascular (extracardiac) disorders 2 (1.8)
Thrombophlebitis deep 1 (0.9)
Cerebral infarction 1 (0.9)
Gastro-intestinal system disorders 1 (0.9)
Nausea 1 (0.9)
Resistance mechanism disorders 1 (0.9)
Sepsis 1 (0.9)
Liver and biliary system disorders 1 (0.9)
Hepatitis 1 (0.9)
Musculo-skeletal system disorders 1 (0.9)
Myositis 1 (0.9)
White cell and RES* disorders 1 (0.9)
Agranulocytosis 1 (0.9)
Myo-, endo-, pericardial & valve disorders 1 (0.9)
Pericarditis 1 (0.9)
Platelet, bleeding & clotting disorders 1 (0.9)
Thrombocytopenia 1 (0.9)

*RES: Reticuloendothelial System

Yakhak Hoeji 2022;66:49-57 https://doi.org/10.17480/psk.2022.66.2.49
© 2022 Yakhak Hoeji